News
AGEN
7.14
+4.47%
0.31
Agenus Strengthens Board With New Director Appointment
TipRanks · 21h ago
Agenus Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
Benzinga · 1d ago
Agenus price target lowered to $25 from $30 at H.C. Wainwright
TipRanks · 1d ago
Weekly Report: what happened at AGEN last week (0803-0807)?
Weekly Report · 2d ago
Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest Review
TipRanks · 2d ago
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Agenus Offers Up To 77,976,718 Shares Of Common Stock By Selling Securityholders
Benzinga · 4d ago
Agenus files to sell 77.98M shares of common stock for holders
TipRanks · 4d ago
Agenus: Q2 Earnings Snapshot
Barchart · 5d ago
Agenus reports Q2 revenue $34.5M vs $25.7M last year
TipRanks · 6d ago
Agenus reports Q2 results
Seeking Alpha · 6d ago
*Agenus Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Dow Jones · 6d ago
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Benzinga · 6d ago
Press Release: Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Dow Jones · 6d ago
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 08/04 12:50
Weekly Report: what happened at AGEN last week (0727-0731)?
Weekly Report · 08/03 10:26
Agenus Is Maintained at Buy by B. Riley Securities
Dow Jones · 07/30 16:39
Press Release: Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Dow Jones · 07/28 20:39
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Barchart · 07/28 15:30
More
Webull provides a variety of real-time AGEN stock news. You can receive the latest news about Agenus through multiple platforms. This information may help you make smarter investment decisions.
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.